Biotage AB appointment of new CEO
Advertisement
BiotageAB announced the appointment of Frederic Vanderhaegen as chief executive officer, effective September 16th 2024. Mr. Vanderhaegen succeeds Torben Jørgensen, who stepped in as interim CEO in January 2024 and he will now continue as a board member.
Frederic Vanderhaegen is a prominent life science leader with 30+ years’ experience leading complex organisations with portfolios including laboratory products, diagnostics, and medical devices. He is ideally positioned to lead the company through its next ambitious phase of growth.
Frederic joins Biotage from Avantor where he was General Manager and Executive Vice President for Europe. He also led the global portfolio for the life science business, sourcing and commercial excellence teams. Prior to Avantor, he worked for Ortho Clinical Diagnostics, Danaher, Tecan and Millipore in various senior leadership positions.
Frederic holds a Biochemical Engineering degree from Haute Ecole Lucia Debroeckere, a Chemical and Agricultural Engineering degree from Universite Libre de Bruxelles and an MBA from the Open University.
Most read news
Other news from the department business & finance
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Dr. Christine Munz becomes CEO at Eppendorf - Dr. Wilhelm Plüster completes term in office as planned
Beckman Coulter Life Sciences Names Joe Fox President
Nobel Prize in Medicine for immune system guardians - Two Americans and one Japanese scientist honored for revolutionary discoveries on the balance of the immune system in autoimmune diseases
GEA Supervisory Board takes early decision to extend contract of CEO Stefan Klebert - Company resolves to restructure the Executive Board and streamline the organizational structure as of January 1, 2026
Mosaic Therapeutics appoints Thomas Fuchs as CEO - Former CEO of Cimeio Therapeutics, and Global Haematology Franchise Head at Roche-Genentech, brings extensive track record of strategic and operational leadership
WIKA strengthens management team with Axel Schwerdtfeger - Process Solutions company division under new leadership
Otto Warburg Medal 2026 awarded to Maya Schuldiner
Research on rewiring neural circuit in fruit flies wins 2025 Eppendorf & Science Prize
Insilico Medicine-led study combines quantum computing and generative AI for drug discovery - “Quantum computing is recognized as the next technology breakthrough which will make a great impact, and the pharmaceutical industry is believed to be among the first wave of industries benefiting from the advancement”
Waters Corporation and Princeton University Announce Multi-Year Research Collaboration - Agreement to take on real-world challenges in biologics and materials research
New biotech venture PHIOGEN to tackle the global threat of antimicrobial resistance - By optimizing nature’s defenders, the team has produced unprecedented phage treatments